{"meta":{"query_hash":"d262bead7696","filters":{"venue":"Revista Colombiana de Gastroenterología"},"cohort_total":1,"direct_labels_cover":0,"predictions_cover":1,"exported":1,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/d262bead7696","api":"https://metacan.xera.ac/api/v1/cohort?venue=Revista+Colombiana+de+Gastroenterolog%C3%ADa"},"results":[{"id":"W2139767739","doi":"","title":"Tratamiento médico para enfermedad inflamatoria intestinal","year":2007,"lang":"es","type":"article","venue":"Revista Colombiana de Gastroenterología","topic":"Microscopic Colitis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Ulcerative colitis; Infliximab; Inflammatory bowel disease; Adalimumab; Intensive care medicine; Crohn's disease; Disease; Inflammatory Bowel Diseases; Quality of life (healthcare); Internal medicine","score_opus":0.017344785937681215,"score_gpt":0.3077368439718635,"score_spread":0.2903920580341823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139767739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98669565,0.0019531345,0.005231307,0.0013000554,0.0008094627,0.0014248436,0.000115100964,0.0003198588,0.0021505672],"genre_scores_gemma":[0.99183667,0.0004012176,0.0022606528,0.0027717222,0.0013065429,0.000054202177,0.000115690294,0.0001210221,0.0011322959],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99349123,0.0003991509,0.001696357,0.0010916361,0.00071814033,0.002603501],"domain_scores_gemma":[0.996136,0.00033377754,0.00063314557,0.0012617253,0.0003277088,0.0013076067],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023059107,0.00080693484,0.0013795065,0.0004589421,0.00023084221,0.00037581587,0.0007242632,0.0004707748,0.00092638226],"category_scores_gemma":[0.0010803785,0.00088679505,0.00044318585,0.00056028715,0.0006298266,0.00018691982,0.00034623969,0.0012523191,0.00037408937],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002530813,0.0006348006,0.94551027,0.0012718628,0.00030873375,0.0021569415,0.0003387957,0.0000011192068,0.022692686,0.0027968418,0.017182412,0.0045747375],"study_design_scores_gemma":[0.0046265447,0.004463362,0.8907595,0.0024930255,0.0006595546,0.0015612699,0.0002494656,0.00014709926,0.00097183086,0.000028746697,0.093623206,0.0004163725],"about_ca_topic_score_codex":0.0003937873,"about_ca_topic_score_gemma":0.00029725305,"teacher_disagreement_score":0.076440796,"about_ca_system_score_codex":0.0014438308,"about_ca_system_score_gemma":0.00057998864,"threshold_uncertainty_score":0.9999869},"labels":[],"label_agreement":null}]}